https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-opens-sleep-facility-nevada BiopharmaWatch en 2026-08-20T14:24:00.000Z Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment https://www.biopharmawatch.com/news/COSM/cosmos-health-exclusive-distribution-agreement-saudi-arabia BiopharmaWatch en 2026-08-20T13:30:00.000Z Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term https://www.biopharmawatch.com/news/PLRZ/polyrizon-completes-nasarix-study-site-network BiopharmaWatch en 2026-08-20T13:30:00.000Z Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment https://www.biopharmawatch.com/news/CELZ/creative-medical-completes-adapt-trial-enrollment BiopharmaWatch en 2026-08-20T13:15:00.000Z Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning https://www.biopharmawatch.com/news/BMY/chai-discovery-collaboration-bms-ai-antibody-discovery BiopharmaWatch en 2026-08-20T13:00:00.000Z Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery https://www.biopharmawatch.com/news/LFST/lifestance-health-foundation-afsp-partnership-renewal BiopharmaWatch en 2026-08-20T13:00:00.000Z LifeStance Health Foundation Renews Partnership with the American Foundation for Suicide Prevention to Advance Mental Health Research https://www.biopharmawatch.com/news/IVF/invo-fertility-prp-research-midwest-symposium-2026 BiopharmaWatch en 2026-08-20T13:00:00.000Z INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-patent-allowance-art27-13 BiopharmaWatch en 2026-08-20T12:52:00.000Z Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-expands-tru-niagen-retail-footprint BiopharmaWatch en 2026-08-20T12:32:00.000Z Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club https://www.biopharmawatch.com/news/FBLG/fibrobiologics-australian-patent-cannabidiol-therapy BiopharmaWatch en 2026-08-20T12:30:00.000Z FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-20T12:30:00.000Z Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/PFSA/profusa-q2-2026-results-g3-vision-labs-option-agreement BiopharmaWatch en 2026-08-20T12:30:00.000Z Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company https://www.biopharmawatch.com/news/SLGL/sol-gel-q2-2026-financial-results-corporate-updates BiopharmaWatch en 2026-08-20T12:30:00.000Z Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/RNXT/renovorx-us-patent-allowance-renovocath-drug-delivery BiopharmaWatch en 2026-08-20T12:30:00.000Z RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment https://www.biopharmawatch.com/news/HYPR/hyperfine-fda-clearance-optive-ai-software BiopharmaWatch en 2026-08-20T12:15:00.000Z Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings https://www.biopharmawatch.com/news/ICCM/icecure-choicem-study-breast-cancer-cryoablation BiopharmaWatch en 2026-08-20T12:10:00.000Z West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-fda-fast-track-lti-03-ipf BiopharmaWatch en 2026-08-20T12:00:17.000Z Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-painweek-2026-symposium BiopharmaWatch en 2026-08-20T12:00:00.000Z Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium https://www.biopharmawatch.com/news/CRL/charles-river-medigen-vaccine-collaboration BiopharmaWatch en 2026-08-20T12:00:00.000Z Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reverse-stock-split-2026 BiopharmaWatch en 2026-08-20T12:00:00.000Z bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026 https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-gx-03-skin-inflammation-research BiopharmaWatch en 2026-08-20T12:00:00.000Z Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch https://www.biopharmawatch.com/news/ADAG/adagene-participate-investor-conferences-2026 BiopharmaWatch en 2026-08-20T12:00:00.000Z Adagene to Participate in Three Upcoming Investor Conferences https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-baird-morgan-stanley-conferences BiopharmaWatch en 2026-08-20T12:00:00.000Z Alignment Healthcare to Present in Baird 2026 Global Healthcare Conference and Attend Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-phase-1-2a-lithium-neuroimaging-data BiopharmaWatch en 2026-08-20T12:00:00.000Z Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC https://www.biopharmawatch.com/news/NUVB/nuvation-bio-fda-fast-track-safusidenib-idh1-glioma BiopharmaWatch en 2026-08-20T12:00:00.000Z Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma https://www.biopharmawatch.com/news/CYTK/cytokinetics-esc-congress-2026-presentations BiopharmaWatch en 2026-08-20T11:30:00.000Z Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 https://www.biopharmawatch.com/news/CNSY/cerenome-sno-asco-conference-2026 BiopharmaWatch en 2026-08-20T11:30:00.000Z Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines https://www.biopharmawatch.com/news/IFRX/inflarx-participation-september-investor-conferences BiopharmaWatch en 2026-08-20T11:30:00.000Z InflaRx Announces Participation in September Investor Conferences https://www.biopharmawatch.com/news/EVAX/evaxion-business-update-q2-2026-results BiopharmaWatch en 2026-08-20T11:30:00.000Z Evaxion announces business update and second quarter 2026 financial results https://www.biopharmawatch.com/news/URGN/intragel-urogen-collaboration-advance-oncology-therapies BiopharmaWatch en 2026-08-20T11:05:00.000Z IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies https://www.biopharmawatch.com/news/URGN/urogen-strategic-collaboration-intragel-oncology BiopharmaWatch en 2026-08-20T11:00:00.000Z UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline https://www.biopharmawatch.com/news/IONS/ionis-new-data-severe-hypertriglyceridemia-esc-2026 BiopharmaWatch en 2026-08-20T11:00:00.000Z Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 https://www.biopharmawatch.com/news/ACON/aclarion-university-arizona-clarity-trial-site BiopharmaWatch en 2026-08-20T11:00:00.000Z Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site https://www.biopharmawatch.com/news/GUTS/fractyl-health-commercial-strategy-day-revita-therapy BiopharmaWatch en 2026-08-20T11:00:00.000Z Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-appoints-wes-burwell-chro BiopharmaWatch en 2026-08-20T11:00:00.000Z Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer https://www.biopharmawatch.com/news/NBP/novabridge-first-half-2026-financial-results BiopharmaWatch en 2026-08-20T11:00:00.000Z NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution https://www.biopharmawatch.com/news/HROW/harrow-iheezo-data-patient-discomfort-intravitreal-injections BiopharmaWatch en 2026-08-20T11:00:00.000Z Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections https://www.biopharmawatch.com/news/ACIU/aci-19764-positive-phase-1-data BiopharmaWatch en 2026-08-20T11:00:00.000Z AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-advances-rad202-phase-1-trial BiopharmaWatch en 2026-08-20T11:00:00.000Z Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial https://www.biopharmawatch.com/news/BNTX/biontech-wclc-2026-lung-cancer-pipeline-progress BiopharmaWatch en 2026-08-20T09:30:00.000Z BioNTech präsentiert auf der WCLC 2026 Fortschritte ihrer spätklinischen Pipeline bei Lungenkrebs und erste globale Daten zur innovativen Behandlungskombination aus Pumitamig und Elfetabart Drozuntecan https://www.biopharmawatch.com/news/BNTX/biontech-lung-cancer-pipeline-wclc-2026 BiopharmaWatch en 2026-08-20T09:30:00.000Z BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026 https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-upsized-public-offering BiopharmaWatch en 2026-08-20T03:06:00.000Z Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock https://www.biopharmawatch.com/news/EDSA/edesa-biotech-pricing-public-offering BiopharmaWatch en 2026-08-20T02:20:00.000Z Edesa Biotech Announces Pricing of $25.0 Million Public Offering https://www.biopharmawatch.com/news/TLX/telix-2026-half-year-results-commercial-execution BiopharmaWatch en 2026-08-20T00:32:00.000Z Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline https://www.biopharmawatch.com/news/PMI/picard-medical-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-19T21:30:00.000Z Picard Medical Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RARE/ultragenyx-fda-approval-genglycos-gsdia BiopharmaWatch en 2026-08-19T21:22:00.000Z Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa) https://www.biopharmawatch.com/news/RARE/ultragenyx-fda-approval-genglycos-gsdia BiopharmaWatch en 2026-08-19T21:22:00.000Z Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa) https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-jefferies-conference-2026 BiopharmaWatch en 2026-08-19T20:30:00.000Z Guardian Pharmacy Services, Inc., to Participate in Upcoming Jefferies Healthcare Services Investor Conference https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-webcast-fy2026-results BiopharmaWatch en 2026-08-19T20:30:00.000Z Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results https://www.biopharmawatch.com/news/SERA/sera-prognostics-appoints-scott-gleason-cfo BiopharmaWatch en 2026-08-19T20:30:00.000Z SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER https://www.biopharmawatch.com/news/ALVO/alvotech-financial-results-business-update-2026 BiopharmaWatch en 2026-08-19T20:30:00.000Z Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update https://www.biopharmawatch.com/news/LGVN/longeveron-appoints-nirav-jhaveri-cfo BiopharmaWatch en 2026-08-19T20:05:00.000Z Longeveron Appoints Nirav Jhaveri as Chief Financial Officer https://www.biopharmawatch.com/news/MMSI/merit-medical-global-operations-leadership-transition BiopharmaWatch en 2026-08-19T20:05:00.000Z Merit Medical Announces Global Operations Leadership Transition https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2026-results BiopharmaWatch en 2026-08-19T20:05:00.000Z Accuray Reports Fourth Quarter and Fiscal 2026 Financial Results https://www.biopharmawatch.com/news/EDSA/edesa-biotech-proposed-public-offering BiopharmaWatch en 2026-08-19T20:01:00.000Z Edesa Biotech Announces Proposed Public Offering https://www.biopharmawatch.com/news/ACB/aurora-cannabis-acquisition-internode-hap-pharma BiopharmaWatch en 2026-08-19T17:45:00.000Z Aurora Cannabis Furthers Global Medical Cannabis Growth with Accretive Acquisition of Internode Pharma Limited and HAP Pharma Limited, Expanding Distribution Access to the UK Medical Cannabis Market https://www.biopharmawatch.com/news/CGEM/zipalertinib-phase-3-rezilient3-trial-results BiopharmaWatch en 2026-08-19T16:00:00.000Z Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer https://www.biopharmawatch.com/news/CGEM/zipalertinib-phase-3-rezilient3-trial-results-iaslc-2026 BiopharmaWatch en 2026-08-19T16:00:00.000Z Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer https://www.biopharmawatch.com/news/BMY/one-mind-music-festival-2026 BiopharmaWatch en 2026-08-19T13:05:00.000Z FESTIVAL ANNOUNCEMENT: 32nd Annual One Mind Music Festival Presented by Bank of America and Bristol Myers Squibb https://www.biopharmawatch.com/news/INCR/intercure-reverse-share-split-nasdaq-compliance BiopharmaWatch en 2026-08-19T13:00:00.000Z InterCure Ltd. Announces 1-for-5 Reverse Share Split https://www.biopharmawatch.com/news/HSCS/fortitude-invests-1-million-heartsciences-premium BiopharmaWatch en 2026-08-19T13:00:00.000Z Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration https://www.biopharmawatch.com/news/REVB/revelation-biosciences-avance-clinical-phase-2-3-study BiopharmaWatch en 2026-08-19T13:00:00.000Z Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study https://www.biopharmawatch.com/news/FEMY/femasys-fda-approval-fembloc BiopharmaWatch en 2026-08-19T13:00:00.000Z Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® https://www.biopharmawatch.com/news/BMY/hematogenix-mm-mrd-assay-fda-approval-zenbexus BiopharmaWatch en 2026-08-19T12:32:00.000Z Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-fiscal-2026-revenue-growth BiopharmaWatch en 2026-08-19T12:30:00.000Z Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-merger-update-phase-2-trial BiopharmaWatch en 2026-08-19T12:26:00.000Z Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/MXCT/maxcyte-launches-change-seq-be-one-seq-be-off-target-assays BiopharmaWatch en 2026-08-19T12:05:00.000Z MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies https://www.biopharmawatch.com/news/AEON/aeon-reports-expanded-structural-data-abp-450-botox BiopharmaWatch en 2026-08-19T12:00:31.000Z AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX® https://www.biopharmawatch.com/news/AEON/aeon-reports-expanded-structural-data-abp-450-botox BiopharmaWatch en 2026-08-19T12:00:31.000Z AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX® https://www.biopharmawatch.com/news/BAX/baxter-appoints-john-rogers-cfo BiopharmaWatch en 2026-08-19T12:00:00.000Z Baxter Appoints John Rogers Chief Financial Officer https://www.biopharmawatch.com/news/HUMA/humacyte-lancet-digital-health-v007-trial-results BiopharmaWatch en 2026-08-19T12:00:00.000Z Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results https://www.biopharmawatch.com/news/MNPR/monopar-appoints-dr-kent-alxn1840-presentations-aasld-2026 BiopharmaWatch en 2026-08-19T12:00:00.000Z Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026 https://www.biopharmawatch.com/news/ZEPP/zepp-health-q2-2026-financial-results-report BiopharmaWatch en 2026-08-19T11:30:00.000Z Zepp Health Corporation to Report Second Quarter 2026 Financial Results on September 1, 2026 https://www.biopharmawatch.com/news/ACB/aurora-cannabis-shareholders-no-action-curaleaf-bid BiopharmaWatch en 2026-08-19T11:05:00.000Z AURORA CANNABIS INC. URGES SHAREHOLDERS TO TAKE NO ACTION AT THIS TIME IN RESPECT TO THE UNSOLICITED TAKE-OVER BID BY CURALEAF HOLDINGS, INC. https://www.biopharmawatch.com/news/SGHT/tearcare-fda-indication-improves-meibomian-gland-function BiopharmaWatch en 2026-08-19T11:05:00.000Z TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-licenses-kio-301-south-korea BiopharmaWatch en 2026-08-19T11:00:00.000Z Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation https://www.biopharmawatch.com/news/GKOS/glaukos-participation-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-19T11:00:00.000Z Glaukos Announces Participation in Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/PLSM/pulsenmore-home-ultrasound-expansion-ichilov BiopharmaWatch en 2026-08-19T11:00:00.000Z Pulsenmore Expands Its Home Ultrasound Activity in Israel: Ichilov Adopts the Technology, Expanding Access to At-Home Pregnancy Monitoring https://www.biopharmawatch.com/news/NSRX/nasus-pharma-cfo-transition BiopharmaWatch en 2026-08-19T11:00:00.000Z Nasus Pharma Announces Transition of Chief Financial Officer https://www.biopharmawatch.com/news/MRK/merck-moderna-phase-3-int-trial-results BiopharmaWatch en 2026-08-19T10:45:00.000Z Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma https://www.biopharmawatch.com/news/IDYA/ideaya-genentech-collaboration-kras-cancer-trial BiopharmaWatch en 2026-08-19T10:00:00.000Z IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer https://www.biopharmawatch.com/blog/phase-2-3-readouts-week-of-2026-08-17 BiopharmaWatch en 2026-08-19T07:15:33.495Z Upcoming Phase 3 Readouts: Key Insights and Expectations https://www.biopharmawatch.com/news/PBM/psyence-biomed-accelerate-ibogaine-development BiopharmaWatch en 2026-08-19T06:27:33.000Z Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development https://www.biopharmawatch.com/news/NVS/novartis-esc-congress-2026-cardiovascular-leadership BiopharmaWatch en 2026-08-19T05:15:00.000Z Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies https://www.biopharmawatch.com/news/GLMD/galmed-successful-first-in-human-study-colospan-technology BiopharmaWatch en 2026-08-19T00:00:00.000Z Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in Israel. The primary objective was to... https://www.biopharmawatch.com/news/IMCC/im-cannabis-30-1-share-consolidation-nasdaq-compliance BiopharmaWatch en 2026-08-18T21:01:00.000Z IM Cannabis Announces Intention to Complete 30:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance https://www.biopharmawatch.com/news/AUNA/auna-announces-2q26-financial-results BiopharmaWatch en 2026-08-18T20:57:00.000Z Auna Announces 2Q26 Financial Results https://www.biopharmawatch.com/news/BAX/baxter-upsized-cash-tender-offers-pricing BiopharmaWatch en 2026-08-18T20:56:00.000Z Baxter Announces Pricing for Its Upsized Cash Tender Offers https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-kol-event-parp-inhibitors-oncology BiopharmaWatch en 2026-08-18T20:15:00.000Z Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald https://www.biopharmawatch.com/news/SILO/silo-pharma-canadian-patent-ptsd-treatment BiopharmaWatch en 2026-08-18T20:15:00.000Z Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment https://www.biopharmawatch.com/news/ONC/beone-medicines-extend-partnership-brukinsa-access BiopharmaWatch en 2026-08-18T20:09:00.000Z Samenvatting: BeOne Medicines, BeOne Care Foundation en The Max Foundation verlengen samenwerking om toegang tot BRUKINSA® voor de behandeling van chronische lymfatische leukemie in lage- en middeninkomenslanden te vergroten https://www.biopharmawatch.com/news/IRIX/iridex-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-18T20:05:00.000Z Iridex Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-350-million-offering BiopharmaWatch en 2026-08-18T20:01:00.000Z Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock https://www.biopharmawatch.com/news/HALO/halozyme-appoints-dannielle-appelhans-board-directors BiopharmaWatch en 2026-08-18T20:01:00.000Z Halozyme Appoints Dannielle Appelhans to its Board of Directors https://www.biopharmawatch.com/news/LIMN/liminatus-pharma-reverse-stock-split BiopharmaWatch en 2026-08-18T20:01:00.000Z Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock https://www.biopharmawatch.com/news/ONC/beone-medicines-renews-partnership-brukinsa-access BiopharmaWatch en 2026-08-18T19:56:00.000Z BeOne Medicines ومؤسسة BeOne Care Foundation ومؤسسة The Max Foundation تجدد شراكتها لتوسيع نطاق الوصول إلى BRUKINSA®‎ لعلاج سرطان الدم الليمفاوي المزمن في البلدان ذات الدخل المنخفض والمتوسط https://www.biopharmawatch.com/news/ONC/beone-medicines-renews-collaboration-brukinsa-access BiopharmaWatch en 2026-08-18T19:18:00.000Z Riassunto: BeOne Medicines, BeOne Care Foundation e The Max Foundation rinnovano la collaborazione per ampliare l'accesso a BRUKINSA® per il trattamento della leucemia linfatica cronica nei Paesi a reddito medio-basso https://www.biopharmawatch.com/news/BLLN/cfDNA-fetal-risk-assessment-general-risk-pregnancies BiopharmaWatch en 2026-08-18T16:08:00.000Z Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions